Higher doses of fulvestrant prolonged survival in patients with advanced breast cancer
Wednesday, December 5, 2012 - 10:30
in Health & Medicine
Increasing the dose of fulvestrant from 250 mg to 500 mg improved median overall survival in women with locally advanced or metastatic estrogen receptor-positive breast cancer, according to updated data.